Start-Up Quarterly Statistics, Q2 2008
This article was originally published in Start Up
Start-Up analyzes fundraising and alliances among emerging companies in the biopharmaceutical, medical device and in vitro diagnostics segments from April through June 2008. Data comes from Windhover's Strategic Transactions Database.
You may also be interested in...
The general economic malaise closed the IPO window for medical device companies, forcing many to withdraw their public financing plans. Companies are adopting various financing and operational strategies to make a best of a bad situation.
Pathway-oriented platforms are rare, and dealmaking around them can be complicated: partner too early or for too little and you risk giving away the store. But Sirtris pulled it off, via M&A, when GSK tendered a whopping $720 million for it in April. The deal is another example of Pharma's interest in platform biotechs and its hunger for innovation. But the unique nature of Sirtris's platform -- broad, but around a single set of biological targets -- makes it more one-off than trend-setting.
Start-Up analyzes fundraising and alliances among start-ups in the biopharmaceutical, medical device and in vitro diagnostics segments from January through March 2008. Data comes from Windhover’s Strategic Transactions Database.